Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation-Reference-Cited by-同舟云学术

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation

Published:2017-04-07 Issue:15 Volume:123 Page:2875-2880
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Nicolini Franck E.¹,Basak Grzegorz W.²,Kim Dong-Wook³,Olavarria Eduardo⁴,Pinilla-Ibarz Javier⁵,Apperley Jane F.⁴,Hughes Timothy⁶,Niederwieser Dietger⁷,Mauro Michael J.⁸,Chuah Charles⁹,Hochhaus Andreas¹⁰,Martinelli Giovanni¹¹,DerSarkissian Maral¹²,Duh Mei Sheng¹²,McGarry Lisa J.¹³,Kantarjian Hagop M.¹⁴,Cortes Jorge E.¹⁴

Affiliation:

1. Hematology Department; Lyon South-Pierre-Bénite Hospital Center and Unit 1052, National Institute of Health and Medical Research Lyon Cancer Research Center/Léon Berard Center; Lyon France

2. Department of Hematology; Oncology and Internal Medicine, Medical University of Warsaw; Warsaw Poland

3. Leukemia Research Institute; Seoul St. Mary's Hospital, The Catholic University of Korea; Seoul Korea

4. Department of Haematology; Imperial College London, Hammersmith Hospital; London United Kingdom

5. H. Lee Moffitt Cancer Center and Research Institute; Tampa Florida

6. Department of Pathology; Royal Adelaide Hospital; Adelaide South Australia Australia

7. Department of Haematology and Medical Oncology, University of Leipzig; Leipzig Germany

8. Department of Leukemia; Memorial Sloan Kettering Cancer Center; New York New York

9. Department of Haematology; Singapore General Hospital, Duke-NUS Medical School; Singapore

10. Clinic and Polyclinic for Internal Medicine II, Division of Hematology and Oncology; Jena University Hospital; Jena Germany

11. L. e A. Seragnoli Institute of Hematology; Bologna Italy

12. Analysis Group, Inc; Boston Massachusetts

13. ARIAD Pharmaceuticals, Inc; Cambridge Massachusetts

14. Department of Leukemia; The University of Texas MD Anderson Cancer Center; Houston Texas

Funder

ARIAD Pharmaceuticals, Inc.

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.30558/fullpdf

Reference15 articles.

1. Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia;Fielding;Haematologica.,2010

2. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia;Fielding;Blood.,2010

3. Resistant mutations in CML and Ph(+)ALL-role of ponatinib;Miller;Biologics.,2014

4. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance;O'Hare;Cancer Cell.,2009

5. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants;O'Hare;Cancer Res.,2005

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Myeloid Leukemia: Advance Phases of the Disease;Cancer Consult;2023-11-18

2. An Update on the Management of Advanced Phase Chronic Myeloid Leukemia;Current Hematologic Malignancy Reports;2023-08-31

3. Chronic Myeloid Leukemia in Children and Adolescents;Advances in Pediatrics;2023-08

4. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre‐ and post‐ponatinib era;American Journal of Hematology;2023-07-23

5. Which Second-Line Tyrosine Kinase Inhibitor(s) for Chronic Myeloid Leukemia?;Current Treatment Options in Oncology;2023-04-29